Results 11 to 20 of about 2,524,657 (288)
Silica Nanoparticles in Transmucosal Drug Delivery [PDF]
Pharmaceutics, 2020 Transmucosal drug delivery includes the administration of drugs via various mucous membranes, such as gastrointestinal, nasal, ocular, and vaginal mucosa.
Twana Mohammed M. Ways +3 more
doaj +7 more sources
Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles [PDF]
Acta Pharmaceutica Sinica B, 2019 Nanoparticles are considered to be a powerful approach for the delivery of poorly water-soluble drugs. One of the main challenges is developing an appropriate method for preparation of drug nanoparticles. As a simple, rapid and scalable method, the flash
Jinsong Tao, Shing Fung Chow, Ying Zheng
doaj +2 more sources
Drying stability and permeability advantages of amorphous drug nanoparticles [PDF]
AAPS OpenThe objective of this study was to develop stable amorphous drug nanoparticles with high drug loading and bioavailability advantages to overcome the drug-loading limitations of conventional amorphous solid dispersion (ASD) formulations.
Akshay Narula +3 more
doaj +2 more sources
Studies of PLGA Nanoparticles for Pharmaceutical Applications [PDF]
, 2014 PLGA have already been successfully applied for controlled drug delivery systems by the pharmaceutical industry due to its biocompatibility, biodegradability and ease of processing.
Sun, Yanqi
core +7 more sources
Toxicology of Nanoparticles in Drug Delivery [PDF]
Current Pathobiology Reports, 2021 Nanoparticles have revolutionized biomedicine especially in the field of drug delivery due to their intriguing properties such as systemic stability, level of solubility, and target site specificity. It can, however, be both beneficial and damaging depending on the properties in different environments, thus highlighting the importance of nanotoxicology
Sharma, Swati +2 more
openaire +2 more sources
Microfluidic Nanoparticles for Drug Delivery
Small, 2022 AbstractNanoparticles (NPs) have attracted tremendous interest in drug delivery in the past decades. Microfluidics offers a promising strategy for making NPs for drug delivery due to its capability in precisely controlling NP properties. The recent success of mRNA vaccines using microfluidics represents a big milestone for microfluidic NPs for ...
Yun Liu +4 more
openaire +5 more sources
Dual role of nanoparticles as drug carrier and drug [PDF]
Cancer Nanotechnology, 2011 The conventional chemotherapeutic agents used in the treatment of human malignancies are directed nonspecifically against both malignant and nonmalignant cells, often limiting their efficacy with having serious side effects. Recent development of drug delivery vehicles has opened up the possibility of targeted drug delivery systems with the potential ...
Patra, Hirak Kumar +4 more
openaire +2 more sources
Nanoparticles for Combination Drug Therapy [PDF]
ACS Nano, 2013 Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted ...
Liang, Ma, Manish, Kohli, Andrew, Smith
openaire +2 more sources
Lipid Nanoparticles for Drug Delivery [PDF]
Advanced NanoBiomed Research, 2021 Lipid nanoparticles have attracted significant interests in the last two decades, and have achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the same time, lipid nanoparticles have also demonstrated enormous potential in delivering nucleic acid drugs as evidenced by the approval of two RNA therapies and mRNA ...
Letao Xu +5 more
openaire +4 more sources
Solid Lipid Nanoparticles: A Potential Approach for Dermal Drug Delivery [PDF]
, 2014 Solid lipid nanoparticles (SLNs) have attracted increasing attention during recent years. Due to their unique size dependent properties, lipid nanoparticles offer possibilities to develop new therapeutics.
Conway, Barbara R +3 more
core +1 more source